ALK - anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK + ALCL and peripheral T-cell lymphoma, not otherwise specified

Report from the International Peripheral T-Cell Lymphoma Project

Kerry J. Savage, Nancy Lee Harris, Julie M. Vose, Fred Ullrich, Elaine S. Jaffe, Joseph M. Connors, Lisa M Rimsza, Stefano A. Pileri, Mukesh Chhanabhai, Randy D. Gascoyne, James O. Armitage, Dennis D. Weisenburger

Research output: Contribution to journalArticle

540 Citations (Scopus)

Abstract

The International Peripheral T-Cell Lymphoma Project is a collaborative effort designed to gain better understanding of peripheral T-cell and natural killer (NK)/T-cell lymphomas (PTCLs). A total of 22 institutions in North America, Europe, and Asia submitted clinical and pathologic information on PTCLs diagnosed and treated at their respective centers. Of the 1314 eligible patients, 181 had anaplastic large-cell lymphoma (ALCL; 13.8%) on consensus review: One hundred fifty-nine had systemic ALCL (12.1%) and 22 had primary cutaneous ALCL (1.7%). Patients with anaplastic lymphoma kinasepositive (ALK +) ALCL had a superior outcome compared with those with ALK - ALCL (5-year failure-free survival [FFS], 60% vs 36%; P = .015; 5-year overall survival [OS], 70% vs 49%; P= .016). However, contrary to prior reports, the 5-year FFS (36% vs 20%; P = .012) and OS (49% vs 32%; P = .032) were superior for ALK - ALCL compared with PTCL, not otherwise specified (PTCL-NOS). Patients with primary cutaneous ALCL had a very favorable 5-year OS (90%), but with a propensity to relapse (5-year FFS, 55%). In summary, ALK - ALCL should continue to be separated from both ALK + ALCL and PTCL-NOS. Although the prognosis of ALK - ALCL appears to be better than that for PTCL-NOS, it is still unsatisfactory and better therapies are needed. Primary cutaneous ALCL is associated with an indolent course.

Original languageEnglish (US)
Pages (from-to)5496-5504
Number of pages9
JournalBlood
Volume111
Issue number12
DOIs
StatePublished - Jun 15 2008

Fingerprint

Peripheral T-Cell Lymphoma
Anaplastic Large-Cell Lymphoma
T-cells
Survival
Skin
Northern Asia
Natural Killer T-Cells
T-Cell Lymphoma
North America
Lymphoma
T-Lymphocytes
Recurrence

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

ALK - anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK + ALCL and peripheral T-cell lymphoma, not otherwise specified : Report from the International Peripheral T-Cell Lymphoma Project. / Savage, Kerry J.; Harris, Nancy Lee; Vose, Julie M.; Ullrich, Fred; Jaffe, Elaine S.; Connors, Joseph M.; Rimsza, Lisa M; Pileri, Stefano A.; Chhanabhai, Mukesh; Gascoyne, Randy D.; Armitage, James O.; Weisenburger, Dennis D.

In: Blood, Vol. 111, No. 12, 15.06.2008, p. 5496-5504.

Research output: Contribution to journalArticle

Savage, Kerry J. ; Harris, Nancy Lee ; Vose, Julie M. ; Ullrich, Fred ; Jaffe, Elaine S. ; Connors, Joseph M. ; Rimsza, Lisa M ; Pileri, Stefano A. ; Chhanabhai, Mukesh ; Gascoyne, Randy D. ; Armitage, James O. ; Weisenburger, Dennis D. / ALK - anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK + ALCL and peripheral T-cell lymphoma, not otherwise specified : Report from the International Peripheral T-Cell Lymphoma Project. In: Blood. 2008 ; Vol. 111, No. 12. pp. 5496-5504.
@article{0b33856bd5f7426b938a9786e89384d7,
title = "ALK - anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK + ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project",
abstract = "The International Peripheral T-Cell Lymphoma Project is a collaborative effort designed to gain better understanding of peripheral T-cell and natural killer (NK)/T-cell lymphomas (PTCLs). A total of 22 institutions in North America, Europe, and Asia submitted clinical and pathologic information on PTCLs diagnosed and treated at their respective centers. Of the 1314 eligible patients, 181 had anaplastic large-cell lymphoma (ALCL; 13.8{\%}) on consensus review: One hundred fifty-nine had systemic ALCL (12.1{\%}) and 22 had primary cutaneous ALCL (1.7{\%}). Patients with anaplastic lymphoma kinasepositive (ALK +) ALCL had a superior outcome compared with those with ALK - ALCL (5-year failure-free survival [FFS], 60{\%} vs 36{\%}; P = .015; 5-year overall survival [OS], 70{\%} vs 49{\%}; P= .016). However, contrary to prior reports, the 5-year FFS (36{\%} vs 20{\%}; P = .012) and OS (49{\%} vs 32{\%}; P = .032) were superior for ALK - ALCL compared with PTCL, not otherwise specified (PTCL-NOS). Patients with primary cutaneous ALCL had a very favorable 5-year OS (90{\%}), but with a propensity to relapse (5-year FFS, 55{\%}). In summary, ALK - ALCL should continue to be separated from both ALK + ALCL and PTCL-NOS. Although the prognosis of ALK - ALCL appears to be better than that for PTCL-NOS, it is still unsatisfactory and better therapies are needed. Primary cutaneous ALCL is associated with an indolent course.",
author = "Savage, {Kerry J.} and Harris, {Nancy Lee} and Vose, {Julie M.} and Fred Ullrich and Jaffe, {Elaine S.} and Connors, {Joseph M.} and Rimsza, {Lisa M} and Pileri, {Stefano A.} and Mukesh Chhanabhai and Gascoyne, {Randy D.} and Armitage, {James O.} and Weisenburger, {Dennis D.}",
year = "2008",
month = "6",
day = "15",
doi = "10.1182/blood-2008-01-134270",
language = "English (US)",
volume = "111",
pages = "5496--5504",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "12",

}

TY - JOUR

T1 - ALK - anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK + ALCL and peripheral T-cell lymphoma, not otherwise specified

T2 - Report from the International Peripheral T-Cell Lymphoma Project

AU - Savage, Kerry J.

AU - Harris, Nancy Lee

AU - Vose, Julie M.

AU - Ullrich, Fred

AU - Jaffe, Elaine S.

AU - Connors, Joseph M.

AU - Rimsza, Lisa M

AU - Pileri, Stefano A.

AU - Chhanabhai, Mukesh

AU - Gascoyne, Randy D.

AU - Armitage, James O.

AU - Weisenburger, Dennis D.

PY - 2008/6/15

Y1 - 2008/6/15

N2 - The International Peripheral T-Cell Lymphoma Project is a collaborative effort designed to gain better understanding of peripheral T-cell and natural killer (NK)/T-cell lymphomas (PTCLs). A total of 22 institutions in North America, Europe, and Asia submitted clinical and pathologic information on PTCLs diagnosed and treated at their respective centers. Of the 1314 eligible patients, 181 had anaplastic large-cell lymphoma (ALCL; 13.8%) on consensus review: One hundred fifty-nine had systemic ALCL (12.1%) and 22 had primary cutaneous ALCL (1.7%). Patients with anaplastic lymphoma kinasepositive (ALK +) ALCL had a superior outcome compared with those with ALK - ALCL (5-year failure-free survival [FFS], 60% vs 36%; P = .015; 5-year overall survival [OS], 70% vs 49%; P= .016). However, contrary to prior reports, the 5-year FFS (36% vs 20%; P = .012) and OS (49% vs 32%; P = .032) were superior for ALK - ALCL compared with PTCL, not otherwise specified (PTCL-NOS). Patients with primary cutaneous ALCL had a very favorable 5-year OS (90%), but with a propensity to relapse (5-year FFS, 55%). In summary, ALK - ALCL should continue to be separated from both ALK + ALCL and PTCL-NOS. Although the prognosis of ALK - ALCL appears to be better than that for PTCL-NOS, it is still unsatisfactory and better therapies are needed. Primary cutaneous ALCL is associated with an indolent course.

AB - The International Peripheral T-Cell Lymphoma Project is a collaborative effort designed to gain better understanding of peripheral T-cell and natural killer (NK)/T-cell lymphomas (PTCLs). A total of 22 institutions in North America, Europe, and Asia submitted clinical and pathologic information on PTCLs diagnosed and treated at their respective centers. Of the 1314 eligible patients, 181 had anaplastic large-cell lymphoma (ALCL; 13.8%) on consensus review: One hundred fifty-nine had systemic ALCL (12.1%) and 22 had primary cutaneous ALCL (1.7%). Patients with anaplastic lymphoma kinasepositive (ALK +) ALCL had a superior outcome compared with those with ALK - ALCL (5-year failure-free survival [FFS], 60% vs 36%; P = .015; 5-year overall survival [OS], 70% vs 49%; P= .016). However, contrary to prior reports, the 5-year FFS (36% vs 20%; P = .012) and OS (49% vs 32%; P = .032) were superior for ALK - ALCL compared with PTCL, not otherwise specified (PTCL-NOS). Patients with primary cutaneous ALCL had a very favorable 5-year OS (90%), but with a propensity to relapse (5-year FFS, 55%). In summary, ALK - ALCL should continue to be separated from both ALK + ALCL and PTCL-NOS. Although the prognosis of ALK - ALCL appears to be better than that for PTCL-NOS, it is still unsatisfactory and better therapies are needed. Primary cutaneous ALCL is associated with an indolent course.

UR - http://www.scopus.com/inward/record.url?scp=47049084821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47049084821&partnerID=8YFLogxK

U2 - 10.1182/blood-2008-01-134270

DO - 10.1182/blood-2008-01-134270

M3 - Article

VL - 111

SP - 5496

EP - 5504

JO - Blood

JF - Blood

SN - 0006-4971

IS - 12

ER -